NLS Pharmaceutics (NLSP) has released an update.
NLS Pharmaceutics Ltd., a Swiss biopharmaceutical company, has been granted an extension by the Nasdaq Hearings Panel to meet the continued listing requirements, which includes maintaining a minimum bid price and stockholders’ equity. The company previously faced potential delisting due to non-compliance with these requirements but now has until mid-October 2024 to comply. Despite the extension, there’s no guarantee NLS will meet the necessary conditions for continued listing on the Nasdaq Capital Market.
For further insights into NLSP stock, check out TipRanks’ Stock Analysis page.
